{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:52:11Z","timestamp":1776091931724,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["45\/7\/2020-\/DDI\/BMS"],"award-info":[{"award-number":["45\/7\/2020-\/DDI\/BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11095-026-04034-2","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:52:19Z","timestamp":1771635139000},"page":"731-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted Gene Therapy for Mutated H-ras and C-raf.1 Genes Exhibited Variable Efficacy in Inhibiting Hepatocellular Carcinoma in Rats: A Mechanistic Approach"],"prefix":"10.1007","volume":"43","author":[{"given":"Alankar","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samrat","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramkrishna","family":"Sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rima","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srijita","family":"Gope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapan Kumar","family":"Giri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7854-9680","authenticated-orcid":false,"given":"Biswajit","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"4034_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1061842","volume":"13","author":"K Lu","year":"2022","unstructured":"Lu K, Fan Q, Zou X. Antisense oligonucleotide is a promising intervention for liver diseases. Front Pharmacol. 2022;13: 1061842. https:\/\/doi.org\/10.3389\/fphar.2022.1061842.","journal-title":"Front Pharmacol"},{"issue":"12","key":"4034_CR2","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1517\/14728222.11.12.1587","volume":"11","author":"V Khazak","year":"2007","unstructured":"Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets. 2007;11(12):1587\u2013609. https:\/\/doi.org\/10.1517\/14728222.11.12.1587.","journal-title":"Expert Opin Ther Targets"},{"key":"4034_CR3","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41388-021-02130-8","volume":"41","author":"L Sun","year":"2022","unstructured":"Sun L, Xi S, Zhou Z, Zhang F, et al. Elevated expression of RIT1 hyperactivates RAS\/MAPK signal and sensitizeshepatocellular carcinoma to combined treatment with sorafenib and AKT inhibitor. Oncogene. 2022;41:732\u201344. https:\/\/doi.org\/10.1038\/s41388-021-02130-8.","journal-title":"Oncogene"},{"key":"4034_CR4","first-page":"4951","volume":"30","author":"R Gedaly","year":"2010","unstructured":"Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM. Evers, PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blockingRas\/Raf\/MAPK and PI3K\/AKT\/mTOR pathways. Anticancer Res. 2010;30:4951\u20138.","journal-title":"Anticancer Res"},{"issue":"2","key":"4034_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00280-009-1035-4","volume":"65","author":"T Das","year":"2010","unstructured":"Das T, Patra F, Mukherjee B. Effect of antisense oligomer in controlling c-raf.1 overexpression during diethylnitrosamine-induced hepatocarcinogenesis in rat. Cancer Chemother Pharmacol. 2010;65(2):309\u201318. https:\/\/doi.org\/10.1007\/s00280-009-1035-4.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"26","key":"4034_CR6","doi-asserted-by":"publisher","first-page":"15481","DOI":"10.1073\/pnas.93.26.15481","volume":"93","author":"H Moser","year":"1996","unstructured":"Moser H, Fabbro D. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci U S A. 1996;93(26):15481\u20134. https:\/\/doi.org\/10.1073\/pnas.93.26.15481.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4034_CR7","doi-asserted-by":"crossref","unstructured":"Mukherjee B, Rajagopalan M, Chakraborty S, Ghosh P, Ray M, Sen R, Ehsan I. Hepatocellular carcinoma: diagnosis, molecular pathogenesis, biomarkers, and conventional therapy. In: Mukherjee B, editor. Nanotherapeutics for the Treatment of Hepatocellular Carcinoma, Bentham Science, Singapore; 2022. pp. 1\u201397.\u00a0https:\/\/cambridgescholars.com\/product\/978-1-5275-0713-5\/","DOI":"10.2174\/9789815039740122010003"},{"issue":"6","key":"4034_CR8","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nm0696-668","volume":"2","author":"BP Monia","year":"1996","unstructured":"Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med. 1996;2(6):668\u201375. https:\/\/doi.org\/10.1038\/nm0696-668.","journal-title":"Nat Med"},{"key":"4034_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122680","volume":"348","author":"A Mukherjee","year":"2024","unstructured":"Mukherjee A, Sen R, Al Hoque A, Giri TK, Mukherjee B. H-ras-targeted genetic therapy remarkably surpassed docetaxel treatment in inhibiting chemically induced hepatic tumors in rats. Life Sci. 2024;348: 122680. https:\/\/doi.org\/10.1016\/j.lfs.2024.122680.","journal-title":"Life Sci"},{"key":"4034_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89633-2","volume":"11","author":"FC Herrmann","year":"2021","unstructured":"Herrmann FC. Easy ultrastructural insight into the internal morphology of biological specimens by Atomic Force Microscopy. Sci Rep. 2021;11: 10214. https:\/\/doi.org\/10.1038\/s41598-021-89633-2.","journal-title":"Sci Rep"},{"key":"4034_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.omtn.2020.01.034","volume":"20","author":"S Chakraborty","year":"2020","unstructured":"Chakraborty S, Dlie ZY, Chakraborty S, Roy S, Mukherjee B, Besra SE, Dewanjee S, Mukherjee A, Ojha PK, Kumar V, Sen R. Aptamer-functionalized drug nanocarrier improves hepatocellular carcinoma toward normal by targeting neoplastic hepatocytes. Mol Ther Nucleic Acids. 2020;20:34\u201349. https:\/\/doi.org\/10.1016\/j.omtn.2020.01.034.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4034_CR12","doi-asserted-by":"publisher","first-page":"121467","DOI":"10.1016\/j.lfs.2023.121467","volume":"317","author":"S Chakraborty","year":"2023","unstructured":"Chakraborty S, Chakraborty A, Mukherjee B, Besra SE, Dewanjee S, Mukherjee A, Sen R, Ojha PK, Kumar V, Shaw TK, Ghosh P, Debnath MC, Ghosh MK. Assessment of superiority of HSP70-targeting aptamer-functionalized drug-nanocarrier over non-targeted commercially available counterpart in HCC therapy: in vitro and in vivo investigations and molecular modeling. Life Sci. 2023;317:121467. https:\/\/doi.org\/10.1016\/j.lfs.2023.121467.","journal-title":"Life Sci"},{"issue":"4","key":"4034_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/01.cej.0000236254.01608.33","volume":"16","author":"B Mukherjee","year":"2007","unstructured":"Mukherjee B, Das T, Ghosh S, Datta S. Changes in the antioxidant defense and hepatic drug metabolizing enzyme and isoenzyme levels, 8-hydroxydeoxyguanosine formation and expressions of c-raf.1 and insulin-like growth factor II genes during the stages of development of hepatocellular carcinoma in rats. Eur J Cancer Prev. 2007;16(4):363\u201371. https:\/\/doi.org\/10.1097\/01.cej.0000236254.01608.33.","journal-title":"Eur J Cancer Prev"},{"issue":"3","key":"4034_CR14","first-page":"623","volume":"33","author":"B Mukherjee","year":"2008","unstructured":"Mukherjee B, Mayer D. Dihydrotestosterone interacts with EGFR\/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells. Int J Oncol. 2008;33(3):623\u20139.","journal-title":"Int J Oncol"},{"key":"4034_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1023\/A:1022945107762","volume":"8","author":"JD Ly","year":"2003","unstructured":"Ly JD, Grubb DR, Lawen A. The mitochondrial membrane potential (\u0394\u03c8m) in apoptosis; an update. Apoptosis. 2003;8:115\u201328. https:\/\/doi.org\/10.1023\/A:1022945107762.","journal-title":"Apoptosis"},{"key":"4034_CR16","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/sj.cdd.4400779","volume":"7","author":"S Matsuyama","year":"2000","unstructured":"Matsuyama S, Reed J. Mitochondria-dependent apoptosis and cellular pH regulation. Cell Death Differ. 2000;7:1155\u201365. https:\/\/doi.org\/10.1038\/sj.cdd.4400779.","journal-title":"Cell Death Differ"},{"issue":"2","key":"4034_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3892\/br.2014.411","volume":"3","author":"VR V\u00e1squez-Garz\u00f3n","year":"2015","unstructured":"V\u00e1squez-Garz\u00f3n VR, Beltr\u00e1n-Ram\u00edrez O, Salcido-Neyoy ME, Cervante-Anaya N, Villa-Trevi\u00f1o S. Analysis of gene expression profiles as a tool to uncover tumor markers of liver cancer progression in a rat model. Biomed Rep. 2015;3(2):167\u201372. https:\/\/doi.org\/10.3892\/br.2014.411.","journal-title":"Biomed Rep"},{"issue":"5","key":"4034_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1593\/neo.05841","volume":"8","author":"JI P\u00e9rez-Carre\u00f3n","year":"2006","unstructured":"P\u00e9rez-Carre\u00f3n JI, L\u00f3pez-Garc\u00eda C, Fattel-Fazenda S, Arce-Popoca E, Alem\u00e1n-Lazarini L, Hern\u00e1ndez-Garc\u00eda S, Le Berre V, Sokol S, Francois JM, Villa-Trevi\u00f1o S. Gene expression profile related to the progression of preneoplastic nodules toward hepatocellular carcinoma in rats. Neoplasia. 2006;8(5):373\u201383. https:\/\/doi.org\/10.1593\/neo.05841.","journal-title":"Neoplasia"},{"key":"4034_CR19","doi-asserted-by":"publisher","unstructured":"Mukherjee B.  Nanotherapeutics for the treatment of hepatocellular carcinoma. Bentham Science Publishers; 2022.  https:\/\/doi.org\/10.2174\/97898150397401220101.","DOI":"10.2174\/97898150397401220101"},{"issue":"2","key":"4034_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/019262338201000206","volume":"10","author":"P Bannasch","year":"1982","unstructured":"Bannasch P, Moore MA, Klimek F, Zerban H. Biological markers of preneoplastic foci and neoplastic nodules in rodent liver. Toxicol Pathol. 1982;10(2):19\u201334. https:\/\/doi.org\/10.1177\/019262338201000206.","journal-title":"Toxicol Pathol"},{"issue":"3","key":"4034_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.4254\/wjh.v13.i3.328","volume":"13","author":"AH Hasanin","year":"2021","unstructured":"Hasanin AH, Habib EK, El Gayar N, Matboli M. Promotive action of 2-acetylaminofluorene on hepatic precancerous lesions initiated by diethylnitrosamine in rats: molecular study. World J Hepatol. 2021;13(3):328\u201342. https:\/\/doi.org\/10.4254\/wjh.v13.i3.328.","journal-title":"World J Hepatol"},{"key":"4034_CR22","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1093\/carcin\/12.10.1817","volume":"12","author":"FS Moreno","year":"1991","unstructured":"Moreno FS, Rizzi MBSL, Dagil MLA, et al. Inhibitory effect of B-Carotene on preneoplastic lesions induced in Wiser rats by the resistant hepatocyte model. Carcinogenesis. 1991;12:1817\u201322. https:\/\/doi.org\/10.1093\/carcin\/12.10.1817.","journal-title":"Carcinogenesis"},{"key":"4034_CR23","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/1097-0142(20010901)92:5<1265::aid-cncr1447>3.0.co;2-5","volume":"92","author":"CC Cunningham","year":"2001","unstructured":"Cunningham CC, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Johnston JF, et al. A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer. 2001;92:1265\u201371. https:\/\/doi.org\/10.1002\/1097-0142(20010901)92:5%3c1265::aid-cncr1447%3e3.0.co;2-5.","journal-title":"Cancer"},{"issue":"1","key":"4034_CR24","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1038\/mtna.2014.69","volume":"4","author":"RZ Yu","year":"2015","unstructured":"Yu RZ, Grundy JS, Henry SP, Kim TW, Norris DA, Burkey J, Wang Y, Vick A, Geary RS. Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2\u2019-o-(2-methoxyethyl) modifications. Mol Ther Nucleic Acids. 2015;4(1):e218. https:\/\/doi.org\/10.1038\/mtna.2014.69.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"4034_CR25","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1038\/mtna.2016.26","volume":"5","author":"RZ Yu","year":"2016","unstructured":"Yu RZ, Graham MJ, Post N, Riney S, Zanardi T, Hall S, Burkey J, Shemesh CS, Prakash TP, Seth PP, Swayze EE, Geary RS, Wang Y, Henry S. Disposition and pharmacology of a GalNAc3-conjugated ASO targeting human lipoprotein (a) in mice. Mol Ther Nucleic Acids. 2016;5(5):e317. https:\/\/doi.org\/10.1038\/mtna.2016.26.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"4034_CR26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3390\/molecules22040563","volume":"22","author":"V Sardone","year":"2017","unstructured":"Sardone V, Zhou H, Muntoni F, Ferlini A, Falzarano MS. Antisense oligonucleotide-based therapy for neuromuscular disease. Molecules. 2017;22(4):563. https:\/\/doi.org\/10.3390\/molecules22040563.","journal-title":"Molecules"},{"key":"4034_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46\u201351. https:\/\/doi.org\/10.1016\/j.addr.2015.01.008.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"4034_CR28","doi-asserted-by":"publisher","first-page":"102133","DOI":"10.1016\/j.omtn.2024.102133","volume":"35","author":"E B\u00e4ckstr\u00f6m","year":"2024","unstructured":"B\u00e4ckstr\u00f6m E, Bonetti A, Johnsson P, \u00d6hlin S, Dahl\u00e9n A, Andersson P, Andersson S, Gennemark P. Tissue pharmacokinetics of antisense oligonucleotides. Mol Ther Nucleic Acids. 2024;35(1):102133. https:\/\/doi.org\/10.1016\/j.omtn.2024.102133.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"11","key":"4034_CR29","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/17425255.2021.1992382","volume":"17","author":"M Shadid","year":"2021","unstructured":"Shadid M, Badawi M, Abulrob A. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion. Expert Opin Drug Metab Toxicol. 2021;17(11):1281\u201392. https:\/\/doi.org\/10.1080\/17425255.2021.1992382.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"4034_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.hepres.2004.02.009","volume":"29","author":"YH Hwang","year":"2004","unstructured":"Hwang YH, Choi JY, Kim S, Chung ES, Kim T, Koh SS, Lee B, Bae SH, Kim J, Park YM. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res. 2004;29(2):113\u201321. https:\/\/doi.org\/10.1016\/j.hepres.2004.02.009.","journal-title":"Hepatol Res"},{"key":"4034_CR31","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.2174\/092986711794940833","volume":"18","author":"SK Nayak","year":"2011","unstructured":"Nayak SK, Panesar PS, Kumar H. Nongenotoxic p53-activators and their significance as antitumor therapy of future. Curr Med Chem. 2011;18:1038\u201349. https:\/\/doi.org\/10.2174\/092986711794940833.","journal-title":"Curr Med Chem"},{"issue":"7","key":"4034_CR32","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3748\/wjg.v13.i7.985","volume":"13","author":"YS Guan","year":"2007","unstructured":"Guan YS, La Z, Yang L, He Q, Li P. P53 gene in treatment of hepatic carcinoma: status quo. World J Gastroenterol. 2007;13(7):985\u201392. https:\/\/doi.org\/10.3748\/wjg.v13.i7.985.","journal-title":"World J Gastroenterol"},{"key":"4034_CR33","first-page":"186","volume":"24","author":"R Hanif","year":"2014","unstructured":"Hanif R, Mansoor S. Hep par-1: a novel immunohistochemical marker for differentiating hepatocellular carcinoma from metastatic carcinoma. J Coll Physicians Surg Pak. 2014;24:186\u20139.","journal-title":"J Coll Physicians Surg Pak"},{"issue":"4","key":"4034_CR34","doi-asserted-by":"publisher","first-page":"S361","DOI":"10.1016\/S1590-8658(11)60592-6","volume":"43","author":"M Roncalli","year":"2011","unstructured":"Roncalli M, Terracciano L, Di Tommaso L, David E, Colombo M. Liver precancerous lesions and hepatocellular carcinoma: the histology report. Dig Liver Dis. 2011;43(4):S361\u201372. https:\/\/doi.org\/10.1016\/S1590-8658(11)60592-6.","journal-title":"Dig Liver Dis"},{"issue":"2","key":"4034_CR35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4103\/egjp.egjp_21_22","volume":"42","author":"SA Mohamed","year":"2022","unstructured":"Mohamed SA, Tealeb AMI. The role of heat shock protein 70 and glypican 3 expression in early diagnosis of hepatocellular carcinoma. Egypt J Pathol. 2022;42(2):112\u20136. https:\/\/doi.org\/10.4103\/egjp.egjp_21_22.","journal-title":"Egypt J Pathol"},{"issue":"6","key":"4034_CR36","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/carcin\/bgt111","volume":"34","author":"ME Murphy","year":"2013","unstructured":"Murphy ME. The HSP70 family and cancer. Carcinogenesis. 2013;34(6):1181\u20138. https:\/\/doi.org\/10.1093\/carcin\/bgt111.","journal-title":"Carcinogenesis"},{"issue":"8","key":"4034_CR37","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/35019501","volume":"2","author":"HM Beere","year":"2000","unstructured":"Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Tailor P, Morimoto RI, Cohen GM, Green DR. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol. 2000;2(8):469\u201375. https:\/\/doi.org\/10.1038\/35019501.","journal-title":"Nat Cell Biol"},{"issue":"3","key":"4034_CR38","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3892\/etm.2018.5762","volume":"15","author":"S Tangchirakhaphan","year":"2018","unstructured":"Tangchirakhaphan S, Innajak S, Nilwarangkoon S, Tanjapatkul N, Mahabusrakum W, Watanapokasin R. Mechanism of apoptosis induction associated with ERK1\/2 upregulation via goniothalamin in melanoma cells. Exp Ther Med. 2018;15(3):3052\u20138. https:\/\/doi.org\/10.3892\/etm.2018.5762.","journal-title":"Exp Ther Med"},{"issue":"17","key":"4034_CR39","doi-asserted-by":"publisher","first-page":"10792","DOI":"10.1074\/jbc.273.17.10792","volume":"273","author":"E Berra","year":"1998","unstructured":"Berra E, Diaz-Meco MT, Moscat J. The activation of p38 and apoptosis by the inhibition of Erk is antagonized by the phosphoinositide 3-kinase\/Akt pathway. J Biol Chem. 1998;273(17):10792\u20137. https:\/\/doi.org\/10.1074\/jbc.273.17.10792.","journal-title":"J Biol Chem"},{"issue":"1","key":"4034_CR40","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.phrs.2013.01.007","volume":"70","author":"A de la V\u00e1zquez Torre","year":"2013","unstructured":"de la V\u00e1zquez Torre A, Junyent F, Folch J, Pelegr\u00ed C, Vilaplana J, Auladell C, Beas-Zarate C, Pall\u00e0s M, Verdaguer E, Camins A. PI3 k\/akt inhibition induces apoptosis through p38 activation in neurons. Pharmacol Res. 2013;70(1):116\u201325. https:\/\/doi.org\/10.1016\/j.phrs.2013.01.007.","journal-title":"Pharmacol Res"},{"issue":"7","key":"4034_CR41","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/modpathol.3800146","volume":"17","author":"R Persad","year":"2004","unstructured":"Persad R, Liu C, Wu TT, Houlihan PS, Hamilton SR, Diehl AM, Rashid A. Overexpression of caspase-3 in hepatocellular carcinomas. Mod Pathol. 2004;17(7):861\u20137. https:\/\/doi.org\/10.1038\/modpathol.3800146.","journal-title":"Mod Pathol"},{"issue":"46","key":"4034_CR42","doi-asserted-by":"publisher","first-page":"16254","DOI":"10.1073\/pnas.1418000111","volume":"111","author":"Q Hu","year":"2014","unstructured":"Hu Q, Wu D, Chen W, Yan Z, Yan C, He T, Liang Q, Shi Y. Molecular determinants of caspase-9 activation by the Apaf-1 apoptosome. Proc Natl Acad Sci U S A. 2014;111(46):16254\u201361. https:\/\/doi.org\/10.1073\/pnas.1418000111.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7-8","key":"4034_CR43","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/07853890.2019.1693056","volume":"51","author":"L Sun","year":"2019","unstructured":"Sun L, Yin H, Liu M, Xu G, Zhou X, Ge P, Yang H, Mao Y. Impaired albumin function: a novel potential indicator for liver function damage? Ann Med. 2019;51(7\u20138):333\u201344. https:\/\/doi.org\/10.1080\/07853890.2019.1693056.","journal-title":"Ann Med"},{"issue":"3","key":"4034_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/cld.534","volume":"7","author":"HL Klavan","year":"2016","unstructured":"Klavan HL, Fortune BE. Elevated creatinine in a patient with cirrhosis. Clin Liver Dis (Hoboken). 2016;7(3):48\u201352. https:\/\/doi.org\/10.1002\/cld.534.","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"4","key":"4034_CR45","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s12072-013-9476-6","volume":"7","author":"R Hernaez","year":"2013","unstructured":"Hernaez R, Yeh HC, Lazo M, Chung HM, Hamilton JP, Koteish A, Potter JJ, Brancati FL, Clark JM. Elevated ALT and GGT predict all-cause mortality and hepatocellular carcinoma in Taiwanese male: a case-cohort study. Hepatol Int. 2013;7(4):1040\u20139. https:\/\/doi.org\/10.1007\/s12072-013-9476-6.","journal-title":"Hepatol Int"},{"issue":"6","key":"4034_CR46","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/NEN.0000000000000201","volume":"74","author":"NM Brossier","year":"2015","unstructured":"Brossier NM, Prechtl AM, Longo JF, Barnes S, Wilson LS, Byer SJ, Brosius SN, Carroll SL. Classic Ras proteins promote proliferation and survival via distinct phosphoproteome alterations in neurofibromin-null malignant peripheral nerve sheath tumor cells. J Neuropathol Exp Neurol. 2015;74(6):568\u201386. https:\/\/doi.org\/10.1097\/NEN.0000000000000201.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"4034_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/genes12060800","volume":"12","author":"JM Mu\u00f1oz-F\u00e9lix","year":"2021","unstructured":"Mu\u00f1oz-F\u00e9lix JM, Mart\u00ednez-Salgado C. Dissecting the involvement of Ras GTPases in kidney fibrosis. Genes. 2021;12(6): 800. https:\/\/doi.org\/10.3390\/genes12060800.","journal-title":"Genes"},{"issue":"3","key":"4034_CR48","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.trecan.2023.11.007","volume":"10","author":"S Vilbois","year":"2024","unstructured":"Vilbois S, Xu Y, Ho PC. Metabolic interplay: tumor macrophages and regulatory T cells. Trends Cancer. 2024;10(3):242\u201355. https:\/\/doi.org\/10.1016\/j.trecan.2023.11.007.","journal-title":"Trends Cancer"},{"issue":"1","key":"4034_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01544-7","volume":"17","author":"H Lin","year":"2024","unstructured":"Lin H, Liu C, Hu A, Zhang D, Yang H, Mao Y. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J Hematol Oncol. 2024;17(1): 31. https:\/\/doi.org\/10.1186\/s13045-024-01544-7.","journal-title":"J Hematol Oncol"},{"key":"4034_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2023.105569","volume":"89","author":"K Harada","year":"2023","unstructured":"Harada K, Furukawa H, Kohara H, Nishimura K, Komori H, Okai Y, Arai Y, Yamamoto Y, Yamamoto K, Imanishi A, Shinozawa T. The mechanism of thrombocytopenia caused by cholesterol-conjugated antisense oligonucleotides. Toxicol In Vitro. 2023;89: 105569. https:\/\/doi.org\/10.1016\/j.tiv.2023.105569.","journal-title":"Toxicol In Vitro"},{"issue":"14","key":"4034_CR51","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.7150\/ijbs.64077","volume":"17","author":"A Fan","year":"2021","unstructured":"Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, Lu Y. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci. 2021;17(14):3837\u201349. https:\/\/doi.org\/10.7150\/ijbs.64077.","journal-title":"Int J Biol Sci"},{"key":"4034_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102433","volume":"109","author":"JBE Janssen","year":"2022","unstructured":"Janssen JBE, Medema JP, Gootjes EC, Tauriello DVF, Verheul HMW. Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer. Cancer Treat Rev. 2022;109: 102433. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102433.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"4034_CR53","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrc1097","volume":"3","author":"M Malumbres","year":"2003","unstructured":"Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3(6):459\u201365. https:\/\/doi.org\/10.1038\/nrc1097.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"4034_CR54","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/humu.20748","volume":"29","author":"Y Aoki","year":"2008","unstructured":"Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y. The RAS\/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat. 2008;29(8):992\u20131006. https:\/\/doi.org\/10.1002\/humu.20748.","journal-title":"Hum Mutat"},{"issue":"4","key":"4034_CR55","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1039\/c0ib00144a","volume":"3","author":"J Plati","year":"2011","unstructured":"Plati J, Bucur O, Khosravi-Far R. Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb). 2011;3(4):279\u201396. https:\/\/doi.org\/10.1039\/c0ib00144a.","journal-title":"Integr Biol (Camb)"},{"issue":"1","key":"4034_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023;8(1): 455. https:\/\/doi.org\/10.1038\/s41392-023-01705-z.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"4034_CR57","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","volume":"1773","author":"JA McCubrey","year":"2007","unstructured":"McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263\u201384. https:\/\/doi.org\/10.1016\/j.bbamcr.2006.10.001.","journal-title":"Biochim Biophys Acta"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04034-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04034-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04034-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:54:19Z","timestamp":1776088459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04034-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4034"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04034-2","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}]}}